Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective,Randomized,Double-Blind,Controlled,Multicenter,Phase III Study of Nimotuzumab in Combination With Chemotherapy and Radiotherapy for Patients With Local Advanced Nasopharyngeal Cancer

NCT01074021 is registered in ClinicalTrials.gov with Biotech Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT01074021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01074021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective,Randomized,Double-Blind,Controlled,Multicenter,Phase III Study of Nimotuzumab in Combination With Chemotherapy and Radiotherapy for Patients With Local Advanced Nasopharyngeal Cancer
Lead sponsor
Biotech Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
October 31, 2009
Completion date
August 31, 2016
Enrollment
480 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal cancer